Myriad Genetics, Inc. (NASDAQ:MYGN) has a beta value of 1.46 and has seen 525,661 shares traded in the last trading session. The company, currently valued at $960.39 Million, closed the last trade at $12.85 per share which meant it gained $0.4 on the day or 3.21% during that session. The MYGN stock price is -174.63% off its 52-week high price of $35.29 and 28.09% above the 52-week low of $9.24. If we look at the company’s 10-day average daily trading volume, we find that it stood at 511.5 Million shares traded. The 3-month trading volume is 726.4 Million shares.
The consensus among analysts is that Myriad Genetics, Inc. (MYGN) is a Hold stock at the moment, with a recommendation rating of 3.1. 2 analysts rate the stock as a Sell, while none rate it as Overweight. 6 out of 10 have rated it as a Hold, with 1 advising it as a Buy. 1 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.28.
Myriad Genetics, Inc. (NASDAQ:MYGN) trade information
Sporting 3.21% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Oct 12 when the MYGN stock price touched $13.89- or saw a rise of 7.45%. Year-to-date, Myriad Genetics, Inc. shares have moved -52.79%, while the 5-day performance has seen it change -5.58%. Over the past 30 days, the shares of Myriad Genetics, Inc. (NASDAQ:MYGN) have changed -1.42%. Short interest in the company has seen 9.38 Million shares shorted with days to cover at 0.01.
Wall Street analysts have a consensus price target for the stock at $15.38, which means that the shares’ value could jump 19.69% from current levels. The projected low price target is $8 while the price target rests at a high of $30. In that case, then, we find that the current price level is +133.46% off the targeted high while a plunge would see the stock lose -37.74% from current levels.
Myriad Genetics, Inc. (MYGN) estimates and forecasts
Figures show that Myriad Genetics, Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -15.43% over the past 6 months, with this year growth rate of 112.5%, compared to 14% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are -450% and -130.4% for the next quarter. Revenue growth from the last financial year stood is estimated to be +1.1%.
8 analysts offering their estimates for the company have set an average revenue estimate of $134.53 Million for the current quarter. 8 have an estimated revenue figure of $161.71 Million for the next quarter concluding in December 01, 2020. Year-ago sales stood $186.3 Million and $209.81 Million respectively for this quarter and the next, and analysts expect sales will grow by -27.8% for the current quarter and -22.9% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -35.1% over the past 5 years. Earnings growth for 2020 is a modest -100% while over the next 5 years, the company’s earnings are expected to increase by 8.1%.
Myriad Genetics, Inc. (NASDAQ:MYGN)’s Major holders
Insiders own 1.76% of the company shares, while shares held by institutions stand at 107.18% with a share float percentage of 109.1%. Investors are also buoyed by the number of investors in a company, with Myriad Genetics, Inc. having a total of 319 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 12.63 Million shares worth more than $143.25 Million. As of June 29, 2020, Blackrock Inc. held 16.91% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 8.25 Million shares as of June 29, 2020. The firm’s total holdings are worth over $93.51 Million and represent 11.04% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Core S&P Smallcap ETF and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. As of August 30, 2020, the former fund manager holds about 6.26% shares in the company for having 4675503 shares of worth $62.51 Million while later fund manager owns 3.1 Million shares of worth $41.47 Million as of August 30, 2020, which makes it owner of about 4.15% of company’s outstanding stock.